SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
193 hedge funds and large institutions have $679M invested in SANGAMO THERAPEUTICS INC in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 23 closing their positions.
28% more call options, than puts
Call options by funds: $10M | Put options by funds: $7.84M
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
9% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 65
1.18% less ownership
Funds ownership: 52.97% → 51.79% (-1.2%)
2% less funds holding
Funds holding: 197 → 193 (-4)
25% less capital invested
Capital invested by funds: $911M → $679M (-$232M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.9M |
| 2 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$5.34M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$3.48M |
| 4 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$12.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.82M |
| 4 |
CC
Casdin Capital
New York
|
-$6.58M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.91M |
SGMO Hedge Fund Activity: Q3 2021 in Review
193 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2021, worth a combined $679M — down 25% from $911M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SGMO and 21 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 59 added.
The largest buyer was BlackRock, adding an estimated $14.9M. The largest seller was JP Morgan Chase, cutting an estimated $12.4M.
- 193 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2021, down from 197 in Q2 2021.
- Funds reported $679M of SANGAMO THERAPEUTICS INC stock for Q3 2021, down 25% quarter-over-quarter.
- 21 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2021 and 23 closed out, a net change of -2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2021 was BlackRock, an estimated $14.9M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2021 was JP Morgan Chase, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2021.